Global Glioblastoma Multiforme Market - 2022-2029

Market Overview

Glioblastoma Multiforme Market is expected to grow at a high CAGR of 8.8% during the forecasting period (2022-2029).

Glioblastoma multiforme (GBM) is a malignant type of central nervous system tumor. Globally, GBM accounts for 54% of new gliomas and 45% of primary malignant tumors. GBM can be either intra tentorial (area located below tentorium cerebella) or supratentorial (area located above the tentorium cerebella). New treatments involve drugs that can be used alone or combined with radiotherapy and chemotherapy. Still, there are more chances of reappearance when compared with electric field therapy. Increased research and clinical trials in treating GBM through immunotherapy are expected to account for a significant market growth share.

Market Dynamics

The increasing research and development on glioblastoma multiforme (GBM) are fueling the global market growth. Also, the globally increasing burden of glioblastoma multiforme is pushthe market growth.

The increasing research and development on glioblastoma multiforme (GBM) fuel market growth.

The increasing research and development on the Glioblastoma multiforme (GBM) are fueling the global market growth. For instance, according to Clinical Trials.gov, currently, 4 studies are active and with results for the intervention of Glioblastoma multiforme (GBM); for instance, National Cancer Institute (NCI), Agenus Inc. collaborated study for the Recurrent Glioblastoma, treatment with bevacizumab, a study for Brain Neoplasms treatment with Nivolumab, Temozolomide sponsored by Bristol-Myers Squibb and collaborated by Ono Pharmaceutical Co. Ltd, a study on Adult Giant Cell Glioblastoma treatment with bevacizumab sponsored by Radiation Therapy Oncology Group and collaborated by National Cancer Institute (NCI) and another study to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar), valproic acid (Depakote), and sildenafil (Viagra), when used to treat high-grade glioma, a type of brain tumor sponsored by Virginia Commonwealth University in collaboration with National Cancer Institute (NCI). Furthermore, 139 studies are waiting for results and are either recruiting or have completed the recruitment and are currently active.

The high research expenditure and the reoccurrence of resistance of glioma stem cells against conventional therapies are major hurdles to market growth.

However, the high expenditure on the research, recurrence of GBM, the resistance of glioma stem cells against conventional therapies, neurotoxicity caused by commercialized drugs for GBM, and lack of GBM treatment efficacy lead to an increase in mortality rate may restrain the growth of the market.

Global Glioblastoma multiforme (GBM) Market-Industry analysis.

The glioblastoma multiforme (GBM) market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, research and developments, epidemiology, regulatory, pricing, pipeline analysis, Etc.

COVID-19 Impact Analysis

During the COVID-19 pandemic, the production plants of many companies were down, and transportation across the globe was affected due to COVID-19 restrictions affecting the supply chain of many companies. Moreover, due to the restriction on socializing, regular imaging and other related check-ups were not possible, leaving a majority of the early-stage GBM cases undetected, negatively impacting the glioblastoma multiforme (GBM) market globally.

Segment Analysis

The drug segment is predicted to dominate the glioblastoma multiforme (GBM) market throughout the forecast period (2022-2029)

Temozolomide is expected to account for significant growth in the market owing to the advantages offered by the drug, which include delayed progression without impacting the quality of life with fewer adverse effects of the molecule. Also, methylated or alkylated DNA in the structural anomalies of the drug will produce a good efficacy, thus leading to a higher preference for this drug over the other drugs. On the contrary, pipeline drugs are expected to be the fastest-growing segment during the forecast period due to fewer adverse effects in the adult patient base with the available drug options. For instance, a study sponsored by Bristol-Myers Squibb in collaboration with Ono Pharmaceutical Co. Ltd, titled "A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma" and is estimated to be completed on August 1, 2023.

Geographical Analysis

North America has command over the glioblastoma multiforme (GBM) market.

North America is estimated to have a large market share in the glioblastoma multiforme market over the forecast period (2022-2029); this is because of the increasing incidences of central nervous system cancers in the geriatric population. According to the study done by the National Brain Tumor Society, in 2022, 700,000 are with a primary brain tumor, and around 88,970 more will be diagnosed 2022. Furthermore, according to the ASCO estimation, in 2022, over 25,050 adult United States residents will be diagnosed with brain and spinal cord tumors, and over 4,170 American children under the age of 15 will be diagnosed with brain tumors by the end of 2022. Furthermore, the ASCO estimated that around 18,280 U.S. adults would die from primary cancerous brain and CNS tumors in 2022. Worldwide over 251,329 people died because of a brain tumor in 2020. Moreover, North America has the most advanced and robust healthcare infrastructure and better reimbursement policies, fueling its dominance over the global market during the forecast period.

Competitive Landscape

The key players operating in the global glioblastoma multiforme market are Genentech, Amgen, Merck & Co., Inc., Teva Pharmaceutical Industries, Ltd., Arbor Pharmaceuticals LLC., Sun Pharmaceutical Industries, Ltd., F. Hoffmann-Le Roche AG, Novartis, and Pfizer. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the global glioblastoma multiforme market. For instance, on 04 May 2022, Bristol Myers Squibb received European Commission approval for Opdivo (nivolumab) with chemotherapy as a first-line treatment for patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC). Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

Pfizer

Overview

Pfizer is an American multinational pharmaceutical and biotechnology corporation founded in 1849 and headquartered in the United States. Pfizer is continuously researching and developing new drug products for various diseases.

Product Portfolio

The product portfolio of Pfizer for glioblastoma multiforme (GBM) has ZIRABEV Injection (bevacizumab-bvzr).

The Glioblastoma multiforme (GBM) market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.